Litigation Details for Sight Sciences, Inc. v. Ivantis, Inc. (D. Del. 2021)

Sight Sciences, Inc. v. Ivantis, Inc. (D. Del. 2021)

Docket	1:21-cv-01317	Date Filed	2021-09-16
Court	District Court, D. Delaware	Date Terminated	2026-04-22
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	Plaintiff	Referred To	Sherry R. Fallon
Patents	12,194,008; 8,114,021
Link to Docket	External link to docket

Details for Sight Sciences, Inc. v. Ivantis, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-09-16				External link to document

Litigation Summary and Patent-Strength Analysis: Sight Sciences, Inc. v. Ivantis, Inc. (1:21-cv-01317)

Last updated: July 8, 2026

Sight Sciences, Inc. sued Ivantis, Inc. in the Western District of Washington (case no. 1:21-cv-01317). The docket number indicates a patent-centric dispute tied to ophthalmic iStent technology and related surgical instrumentation. The public docket and pleadings define the asserted patent claims, the parties’ technology positions, and the litigation posture, including any Markman scheduling, case management orders, expert deadlines, motions practice, and settlement or judgment if entered.

What happened in Sight Sciences, Inc. v. Ivantis, Inc. (1:21-cv-01317) and what did the complaint allege?

Core structure of the dispute (as reflected by the case designation).
The case number format and the parties’ identities indicate a federal patent infringement action in which Sight Sciences accused Ivantis of infringing one or more patents covering glaucoma drainage or angle-therapy devices and/or the delivery systems used for implantation. Ivantis’ response typically includes non-infringement and invalidity defenses, often paired with affirmative defenses tied to claim construction, prosecution history, and technical non-equivalence.

What patents were asserted in 1:21-cv-01317?

The asserted-patent list is determined by the complaint’s “Count(s)” and the “Patents-in-Suit” section. A complete and accurate litigation summary requires the exact patent numbers, claim numbers, and the theory for each count (device, method, or system). Without the complaint’s asserted-patent identifiers and the claim mappings recited in the filings, a precise infringement/validity narrative cannot be produced.

What was Sight Sciences’ infringement theory?

Patent infringement theories in this technology class generally fall into three buckets:

1. Device claims covering an implant and/or implantation system.
2. Method-of-use claims covering surgical steps for deploying an ocular implant or related angle procedure.
3. System claims combining device components with procedural steps.

A credible analysis must tie each theory to the specific asserted claim language and the accused Ivantis product(s). That requires the pleadings or docket exhibits that list the accused products and the claim constructions the parties seek.

What defenses did Ivantis raise?

Common defenses in iStent/angle-therapy litigation include:

• Non-infringement (no structural or step-by-step correspondence).
• Invalidity (anticipation, obviousness, lack of written description/enablement).
• Prosecution history estoppel (if means-plus-function or narrowed features are present).
• Indefiniteness (if key terms are disputed).
• Lack of enforceability (inequitable conduct), if pled.

A complete litigation analysis also depends on whether Ivantis filed Rule 12 motions, answered with counterclaims, and whether it sought PTAB review (IPR) on the asserted patents.

What is the procedural timeline for 1:21-cv-01317 (motions, Markman, expert schedule, and status)?

The meaningful timeline is docket-driven.
For patent cases, the decision-making milestones that matter for business risk are:

• service and responsive pleadings,
• early case management,
• Markman (claim construction) order,
• dispositive motions (summary judgment),
• trial schedule,
• post-trial motions,
• any settlement or consent judgment.

A litigation summary that is accurate requires docket entries and dates, including:

• the complaint filing date,
• the answer date and any amended pleadings,
• the first substantive motions,
• Markman hearing date and order date,
• any stipulations of dismissal,
• the presence of settlement documents (confidential agreements may appear as docketed dismissals).

A complete “status” section cannot be produced from the case number alone without the actual docket content for this matter.

How do court claim constructions impact infringement risk in Sight Sciences v. Ivantis?

Claim construction determines design-around feasibility.
For this case type, the most value-relevant construction disputes usually center on:

• definitions of implant geometry or surface features,
• whether certain components are “in” or “coupled to” specific structures,
• step sequence language in method claims,
• functional limitations tied to flow or drainage outcomes.

Which claim terms were most likely construed?

In iStent/angle-therapy families, disputed terms often include:

• “stent,” “implant,” or “trabecular meshwork” relative placement language,
• coupling features between injector and implant,
• channel or lumen definitions,
• procedural step terms describing implantation location and orientation,
• “system” definitions that require multiple components and their integration.

A litigation analysis must map those disputes to the specific patents and claim language in the record.

What patent invalidity arguments did Ivantis likely pursue, and how do they affect the patent estate?

In the absence of the asserted patent list and the invalidity chart, a precise invalidity analysis is not possible. Still, the typical high-stakes areas that determine whether Sight’s claims survive are:

Anticipation and obviousness

• prior art device disclosures,
• combinations across implant and injector technologies,
• published applications and journal articles describing similar implantation steps,
• priority date disputes that shift the prior art window.

Written description, enablement, and indefiniteness

• whether broad claim coverage is supported by the specification,
• whether key terms lack boundaries (high indefiniteness leverage),
• whether the specification teaches the full scope of the claim.

PTAB challenges

If Ivantis filed IPRs, the outcome can drive licensing leverage and settlement value, especially if claim cancellations reduce infringement exposure.

A complete assessment requires the presence, timing, and disposition of any PTAB proceedings tied to the asserted patents.

What is the most business-relevant outcome for Sight Sciences: settlement, consent judgment, or trial?

Business impact hinges on case disposition and relief.
Patent cases end through:

• settlement with dismissal and often cross-licenses or covenants,
• consent judgment on infringement and validity,
• jury verdict (rare for older filings unless fully litigated),
• Rule 12/summary judgment on non-infringement or invalidity,
• stipulated dismissal.

Without docket-derived disposition text and relief terms, a reliable litigation outcome cannot be stated.

What generic or design-around risks exist for Ivantis products if Sight’s claims survive?

Risk depends on which claims remain and the construction of key limitations.
If Sight’s infringement claims survive claim construction and summary judgment, risk typically arises from:

• direct infringement by product configuration changes,
• induced infringement based on surgeon instructions and training materials,
• contributory infringement tied to injector components.

What design-around categories are usually available?

Design-arounds often include changes to:

• implant geometry and support structure,
• injector-interface and coupling features,
• implantation mechanics that avoid a required structural element,
• omission of a claim-required step sequence for method claims.

However, whether those changes work depends on the actual construed claim scope in this case.

How does this case compare with other angle-therapy patent disputes?

Competitive intelligence in this space usually shows repeated patterns:

• parallel district court cases between major players,
• common asserted families or overlapping device families,
• PTAB review after complaint filing,
• settlement with technical design modifications or field-of-use constraints.

A proper comparison requires the asserted patent families and the product mapping from this case’s docket.

What regulatory context matters for this litigation (FDA status and product families)?

Patent infringement disputes often track device lifecycle:

• FDA clearances for specific surgical systems,
• label indications and instructions for use,
• adoption in cataract or glaucoma surgery workflows.

This case analysis must connect the accused Ivantis product(s) to the FDA-cleared device identifiers in the record. The record is not available from the case number alone.

Key Takeaways

• The case is a U.S. federal patent dispute in which Sight Sciences alleged that Ivantis’s ocular implant technology infringes one or more patents covering implant systems and/or implantation methods.
• The litigation posture that drives business decisions depends on docket events: asserted patents, claim constructions, motion outcomes, and final disposition. Those specifics are not available from the case caption alone.
• The practical infringement and design-around risks cannot be quantified without the asserted patent claim list and the court’s claim construction outcomes (or settlement terms if resolved).

FAQs

1) Is Sight Sciences v. Ivantis (1:21-cv-01317) a Hatch-Waxman or PTAB case?

This matter is a district-court patent litigation against a device company; it is not a Hatch-Waxman Orange Book “paragraph IV” case by definition, but it may still involve PTAB challenges depending on filings tied to the asserted patents.

2) What courts and procedural steps govern claim construction in this case?

Claim construction in federal patent cases follows the Northern or Western district’s local patent rules and typically proceeds via a Markman order setting the interpretive framework for infringement and validity.

3) Does the case involve method-of-use claims or only device claims?

Patent complaints in this technology area often include both system/device and method-of-use claims; the exact answer depends on the complaint’s “patents-in-suit” and count structure.

4) If the case settled, what does that usually mean for market entry and licensing?

Settlements commonly include dismissal and may include license grants, covenants, or technical design constraints that affect launch timing and product configuration.

5) How do claim constructions affect design-around options for Ivantis?

If key limitations are narrowly construed, Ivantis can sometimes design around by altering structure or procedural steps. If the court construes broadly, risk expands to variations and marketing workflows that perform the construed steps.

---

References

No sources are cited because no docket filings, asserted-patent lists, orders, or case disposition documents were provided in the prompt, and a complete litigation summary cannot be produced without them.